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1. ABSTRACT 
The production of autoantibodies to self 
antigens is dependent on the failure of immune 
tolerance. Cancer cells express antigens which elicit 
a spontaneous immune response in cancer patients. 
The repertoire of autoantibodies found in cancer 
patients partly covers that of patients with autoimmune 
diseases. Biological activities of autoantibodies to self 
antigens may induce paraneoplastic syndromes which 
reflect the attempt of cancer patients to counteract 
tumor growth. Autoantibodies with similar specificities 
may have different effects in cancer and autoimmune 
disease patients due to different immunological 
microenvironments. Tregs dysfunction has been 
observed in patients with paraneoplastic syndromes 
and/or with autoimmune diseases, while the increase 
of Tregs has been associated with poor cancer patients 
prognosis. Novel therapies have employed antibodies 
against Tregs immune-checkpoint receptors with the 
aim to boost immune response in cancer patients. 
The presence of autoantibodies to tumors antigens 
has also been investigated as a marker for cancer 
detection and cancer patients prognosis. This report 
reviews the current knowledge on the analysis and 
meaning of autoantibodies to self antigens detected in 
cancer and autoimmune disease patients. 
2. INTRODUCTION
The production of autoantibodies to self 
antigens is dependent on the breakdown or failure 
of immune tolerance mechanisms toward self-
antigens. The immune system does not recognizes 
self-antigens in physiological conditions, but after the 
failure of immune tolerance these antigens may elicit 
T and B cells immune response (1). The immune 
response of autoreactive B cells occurs via central and 
peripheral tolerance mechanisms. During the central 
tolerance the autoreactive B cells are eliminated by 
receptor editing, that leads to rearrangement of light-
chain Ig genes to generate a new B cell with non-
self-reactive receptors. During peripheral tolerance, 
the autoreactive B cells are removed via several 
mechanisms, including inhibition mediated by FcγRllb, 
clonal inhibition by the Siglec/SIaE pathway, inhibition 
by T regulatory cells (Tregs) in an MHC class II- and 
CD40L-dependent manner, clonal deletion and anergy 
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(1). In addition, during development autoreactive 
T cells are initially deleted by negative selection in 
thymus and then by peripheral tolerance through 
Tregs, clonal deletion and anergy (2). Thus, defective 
immune tolerance mechanisms affect autoimmunity by 
increasing the prevalence of autoreactive lymphocytes. 
Autoantibodies to self antigens are found both in sera 
from patients with systemic autoimmune diseases 
and with cancer (3, 4). However these autoantibodies 
display a different immunological background leading 
to different effects in cancer and autoimmune disease. 
The presence of serum autoantibodies to abnormally 
expressed tumor antigens might reflect the attempt 
of cancer patients to counteract cancer cells growth, 
while autoantibodies found in autoimmune disease are 
the result of breakdown of self-tolerance and induce 
pro-inflammatory responses and tissue injuries (5). 
3. IMMUNE RESPONSE TO SELF ANTIGENS 
IN CANCER PATIENTS PARTLY COVERS 
THAT CHARACTERISTIC OF PATIENTS WITH 
AUTOIMMUNE DISEASES 
Cancer cells express tumor antigens able 
to elicit a spontaneous immune response in cancer 
patients. Of note, the repertoire of autoantibodies found 
in cancer patients partly covers that characteristic 
of patients with autoimmune diseases (5). These 
autoantibodies might be useful as diagnostic or 
prognostic markers in cancer patients and as serological 
markers for the diagnosis of autoimmune diseases (6, 
7). Table 1 reports examples of autoantibodies found 
both in cancer and autoimmune disease patients (5, 
8-168).
Specific autoantibodies against nuclear anti-
gens were detected both in cancer and in autoimmune 
disease patients. These autoantibodies recognized 
single- and double-stranded DNA, Ro/SS-A, La/SS-B, 
centromere, Jo-1, Smith antigens (Sm), small nuclear 
ribonucleoproteins (snRNP), topoisomerase I and II, 
nucleolar phosphoprotein B23/nucleophosmin, nucle-
olar organizer antigen NOR-90 and RNA polymerase 
III (5, 8-30). For example, anti-Ro/SS-A and anti-La/
SS-B were prevalent in patients with Sjogren’s syn-
drome (13) and systemic lupus erithematosus (SLE) 
(11) and in patients with hematological malignancies 
as well (5). Among the others, autoantibodies to p53, 
MDM-2, c-Myc and c-Myb were frequently detected 
in cancer and autoimmune disease patients. Autoan-
tibodies against p53 were found in gastric, ovarian, 
colorectal, breast, head and neck cancer patients as 
well as in patients with SLE, rheumatoid arthritis (RA), 
dermatomyositis, autoimmune thyroiditis and hepa-
titis, primary biliary cirrhosis and systemic sclerosis 
(5, 31, 32). Autoimmune disease and cancer patients 
have also been found to exhibit autoantibodies against 
MDM-2, which is the p53 inhibitor (33, 34). Anti-c-Myc 
autoantibodies have been reported to occur in patients 
with gastric, breast, colon and ovarian cancer as well 
as in patients with SLE, Graves’ disease, mixed con-
nective tissue disease, dermatomyositis and autoim-
mune hemolytic anemia (5, 27, 34-39). Patients with 
colon, ovarian, breast and lung cancer as well as pa-
tients with SLE have been found to produce autoanti-
bodies against the c-Myb protein (40). Both categories 
of patients generate autoantibodies against cyclin-B1, 
survivin, p16, 14-3-3 proteins, eukaryotic translation 
initiation factor 4G (eIF-4G) and RAF1 (14, 27, 28, 
34-36, 40-48). Autoantibodies against the cyclic citrul-
linated peptide (CCP) were detected in patients with 
Sjogren’s syndrome and psoriatic arthritis (51, 52) as 
well as in lymphoma patients (49). Anti-CCP antibod-
ies are highly specific for RA and have recently been 
used in the clinical classification of this disease. These 
antibodies are more specific than rheumatoid factor 
(RF) for the diagnosis of RA (50). Furthermore, anti-RF 
antibodies are present in about 74% of patients with 
Sjogren’s syndrome, in particular in the early stage of 
disease, and also in patients with autoimmune pancre-
atitis (13). Serum of patients with melanoma, bladder 
and gastrointestinal cancers contain anti-CCP auto-
antibodies as well (53, 54). Circulating autoantibodies 
against smooth muscle antigens (ASMA), including 
actin, troponin and tropomyosin, have been detected 
in patients with hepatocarcinoma, lung, breast, gastric, 
ovarian, melanoma, cervix, thymoma cancers, as well 
as in patients with Sjogren’s syndrome, autoimmune 
hepatitis and pancreatitis, primary biliary cirrhosis and 
other autoimmune diseases (12, 19, 20, 55, 56, 58-
62). The principal autoantibodies against the thyroid 
gland are anti-thyroid peroxidase (TPO), anti-thyro-
globulin (TG) and anti-thyroid stimulating hormone 
receptor (TSH-R). Indeed, anti-TPO and anti-TG anti-
bodies are mainly detected in patients with Hashimo-
to’s thyroiditis, but they also occur in 70% of patients 
with Graves’ disease (169). In addition, patients with 
diabetes, RA, systemic sclerosis, celiac disease, auto-
immune gastritis, Sjogren syndrome as well as cancer 
patients with gastric MALT-type lymphoma, breast and 
thyroid cancer also display autoantibodies anti-TPO 
and anti-TG (5, 51, 63-73). Autoantibodies to extra-
cellular matrix (ECM) components, including collagen, 
fibronectin and laminin, have been reported in RA, au-
toimmune thyroiditis, SLE, systemic sclerosis, Crohn’s 
disease, primary Raynaud’s disease, epidermolysis 
bullosa and pemphigo. Sera from patients with breast, 
prostate, lung and nasopharyngeal cancers displayed 
anti-ECM components autoantibodies (5, 11, 74-80). 
Autoimmune disease and cancer patients also exhib-
it autoantibodies against heat shock proteins (HSP), 
including HSP-60, -70, -90 and glucose-regulated pro-
tein 78 (GRP78).  Autoantibodies against one or more 
HSPs have been found to occur in patients with SLE, 
RA, Sjogren’s syndrome, mixed connective tissue dis-
eases, diabetes, Behҫet’s disease, autoimmune reti-
nopathy, encephalomyelitis and hepatitis, dermatitis 
herpetiformis and juvenile dermatomyositis, as well as 
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Table 1. Examples of autoantibodies to self antigens found both in patients with cancer and autoimmune 
disease.





lymphoma, ovary, HCC, stomach, 
colon-rectum
SLE, AIH-PBC overlap 5, 8-12
Anti-Ro/SS-A Lymphoma, hematological malignancies
SS, SLE, RA, PBC, dermatomyositis, 
SS-SLE overlap, systemic sclerosis 5, 8, 11, 13-15
Anti-La/SS-B Breast, lymphoma, SCLC, hematological malignancies SS, SLE 5, 8, 11, 13
Anti-CENP Breast, SCLC, NHL, HCC SS, SLE, RA, systemic sclerosis, PBC 5, 14, 16-19
Anti-Jo-1 Stomach, lymphoma SS, polymyositis 8, 20, 21
Anti-Sm Hematological malignancies, kidney, lymphoma, gastrointestinal, ovary SLE, mixed connective tissue disease 5, 8, 11, 21
Anti-U1 snRNP Lung SLE, mixed connective tissue disease 5, 11, 22
Anti-U3 snRNP HCC Systemic sclerosis 5, 14
Anti-Topoisomerase I 
(Scl-70) Stomach, lymphoma
Systemic sclerosis, SLE, mixed 
connective tissue disease 8, 14, 20, 21
Anti-Topoisomerase II Breast, HCC
Juvenile RA, diabetes mellitus, SLE, 





HCC, breast, prostate, ovary, 
pancreas, lung, colon
Systemic sclerosis, RA, SLE, 
scleroderma 5, 26-29
Anti-NOR-90 HCC Systemic sclerosis, Raynaud’s syndrome, RA, SLE 5, 14
Anti-RNA Polimerase III Breast Systemic sclerosis 14, 30
Anti-p53
Stomach, ovary, colon-rectum, breast, 
esophagus, head and neck, HCC, 
bladder, lung, cervix, uterus, pancreas, 
lymphoma, biliary tract, hematological 
malignancies, prostate, glioma, skin
SLE, RA, dermatomyositis, AITD, 
AIH, PBC, AIH-PBC overlap, systemic 
sclerosis
5, 31, 32
Anti-MDM2 Lung, prostate SLE, systemic sclerosis 33, 34
Anti-c-Myc
Stomach, lung, breast, colon,
ovary, HCC, hematological 
malignancies, prostate
SLE, Graves’ disease, mixed 




Anti-c-Myb Colon, ovary, breast, lung SLE 40
Anti-Cyclin-B1 Lung, breast, HCC, prostate SLE, systemic sclerosis 27, 34, 36, 40
Anti-Survivin Stomach, ovary, pancreas, lung, colon, breast, HCC, prostate SLE, systemic sclerosis
14, 28, 34, 35, 
41
Anti-p16 Lung, breast, HCC, prostate SLE, systemic sclerosis 27, 34, 36, 42
Anti-14-3-3 proteins Lung, HCC, prostate RA, SLE, systemic sclerosis 27, 34, 43, 44
Anti-eIF-4G Prostate RA 45, 46
Anti-RAF1 Colon-rectum Autoimmune inner ear disease 47, 48
Anti-CCP Diffuse large B-cell lymphoma RA, SS, psoriatic arthritis 49-52





Stomach, HCC, melanoma, lung, 
breast, ovary, cervix, thymoma
SS, AIH, autoimmune pancreatitis, 
PBC, AIH-PBC overlap, celiac 
disease, primary sclerosing 
cholangitis
12, 19, 20, 55, 
56, 58-62




Anti-TPO Gastric MALT-type lymphoma, breast, papillary thyroid
AITD, type 1 diabetes, RA, celiac 
disease, systemic sclerosis, 
autoimmune gastritis
5, 51, 63-68
Anti-TG DTC, papillary thyroid, gastric MALT-type lymphoma






RA, PV, SLE, epidermolysis bullosa, 
systemic sclerosis, Hashimoto’s 
thyroiditis, Graves’ disease, Chron’s 
disease, Raynaud’s disease
5, 74-78
Anti-Fibronectin Nasopharyngeal, prostate RA, SLE, Hashimoto’s thyroiditis 5, 74, 78
Anti-Laminin Breast, prostate
SLE, PV, systemic sclerosis, 





HCC, breast, ovary, osteosarcoma, 
colon-rectum, gastric MALT-type 
lymphoma
Behҫet disease, type 1 diabetes, 
SLE, RA, mixed connective tissue 
disease, autoimmune retinopathy, 
dermatitis herpetiformis, juvenile 
dermatomyositis, AIH
5, 17, 81-86
Anti-HSP70 Breast, HCC, nasopharyngeal Dermatitis herpetiformis, AIH 36, 84, 86-88
Anti-HSP90




autoimmune encephalomyelitis, RA, 
SLE, autoimmune bullous diseases, 
type 1 diabetes, AIH
5, 28, 74, 79, 84, 
86, 89-91
Anti-GRP78 HCC, colon-rectum, prostate, ovary RA, SLE, SS 28, 92-95
Anti-onconeural
antigens
Anti-Hu (ANNA-1) SCLC Autoimmune limbic encephalopathy non paraneoplastic 96, 97
Anti-Ri (ANNA-2) SCLC, breast, ovary Opsoclonus myoclonus syndrome 40, 98
Anti-enzymes
Anti-α-enolase
Lung, pancreatic ductal, breast, 
leukemia, head and neck, melanoma, 
esophagus
SLE, mixed connective tissue 
disease, systemic sclerosis, 
Behҫet’s disease, RA, Hashimoto’s 
encephalopathy, celiac disease, AIH, 
PBC, primary sclerosing cholangitis
5, 99-105
Anti-GAD Lung, breast, thymoma
Type 1 diabetes, non-paraneoplastic
limbic encephalitis, Stiff-person 
syndrome, cerebellar ataxia, Batten 
disease
60, 106-108
Anti-Tyrosinase Melanoma Vitiligo 109
Anti-Transglutaminase Lymphoid malignancies
Celiac disease, autoimmune 
polyendocrine syndrome type 1, SS, 
type 1 diabetes
5, 110, 111
Anti-CA II Pancreas, melanoma
SS, SLE, RA, autoimmune 
pancreatitis, autoimmune 
retinopathies, type 1 diabetes, PBC, 
Graves’ disease, systemic sclerosis, 
autoimmune endometriosis
55, 56, 112-120
Anti-GAPDH HCC SLE 87, 121
Anti-Peroxiredoxin Prostate, breast, esophagus, lung, HCC
SLE, RA, Behҫet’s disease,
vasculitis syndrome, systemic 
sclerosis
14, 36, 87, 122-
126
Anti-SOD HCC, lung RA, SLE 87, 127, 128
Anti-Factor XIII Lymphoid malignancies




Anti-Ribosomal P proteins Head and neck, breast, prostate, colon-rectum
SLE, AIH, mixed connective tissue 
disease 11, 74, 132- 136
Anti-Mitochondrial antigens Breast PBC, SS, AIH, RA, SLE 11, 13, 73, 137, 138
Anti-Centrosome Breast RA, SLE, scleroderma 139
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in patients with osteosarcoma, HCC, breast, ovarian 
and other types of cancer (5, 17, 28, 36, 74, 79, 81-
95). Autoantibodies against onconeural antigens, like 
Hu (ANNA-1) and Ri (ANNA-2) and against enzymes, 
like α-enolase, glutamate decarboxylase (GAD), tyros-
inase, transglutaminase, carbonic anhydrase II (CAII), 
glyceraldehyde 3-phosphate dehydrogenase (GAP-
DH), peroxiredoxin, superoxide dismutase (SOD) and 
coagulation factor XIII, have been reported in both 
patients with autoimmune diseases and cancer (5, 
14, 36, 40, 55, 56, 60, 87, 96-131). Circulating auto-
antibodies against the ribosomal P proteins (P0, P1 
and P2) are directed mainly to the carboxy-terminal 
epitope common to all three proteins and have been 
identified for the first time in SLE patients. Patients 
with autoimmune hepatitis and mixed connective tis-
sue diseases display these antibodies too. We have 
recently demonstrated the presence of autoantibodies 
against P proteins in head and neck, breast, prostate 
and colorectal cancer patients (11, 74, 132-136). Pa-
tients with autoimmune diseases and cancer also ex-
hibit autoantibodies against mitochondrion and centro-
some antigens (11, 13, 73, 137-139). In addition, the 
presence of autoantibodies against several membrane 
receptors, including Fas receptor, estrogen recep-
tor (ER) and acetylcholine receptor (AchR) has been 
reported in sera of patients with various autoimmune 
diseases and with cancer (140-145). Anti-voltage-gat-
ed calcium channel (VGCC), anti-CD20, anti-annexin, 
anti-α-fetoprotein, anti-phospholipid, anti-desmoglein 
(DSG), anti-cytokeratin-8, anti-insulin-like growth fac-
tor II mRNA-binding proteins (IMP), anti-interferon 
(IFN)-α and anti-α2-HSG (Heremans Schmid-glycopro-
tein) autoantibodies have also been found in sera from 
patients with cancer and autoimmune disease (5, 11, 
17, 34-36, 40, 47, 120, 122, 146-168).
4. FEATURES OF SELF ANTIGENS INVOLVED 
IN THE AUTOREACTIVE IMMUNE RESPONSE: 
IMMUNOLOGICAL PROPERTIES AND ABNOR-
MAL EXPRESSION 
The events inducing the generation of 
autoantibodies recognizing common antigens in 
cancer and autoimmune disease patients are still 
not completely clear. However, some theories have 
been proposed. Plotz described that the features 
of self antigens that might induce the production of 
autoantibodies can be related to: a) their structural 
properties; b) their catabolism and fate after cell death; 
Anti-Receptors
Anti-Fas receptor Colon SLE, systemic sclerosis, silicosis 140, 141
Anti-ER Breast SLE, systemic sclerosis 142, 143
Anti-AChR Thymoma Myasthenia gravis 144, 145
Anti-VGCC SCLC Lambert-Eaton syndrome 40, 146
Anti-CD20 NHL, CLL RA, SLE, SS 5, 147, 148
Anti-Annexin Lung, colon-rectum, prostate, breast, ovary
Anti-phospholipid syndrome, SLE, 
RA, systemic sclerosis, connective 




Anti-α-fetoprotein HCC, colon-rectum SLE, juvenile Batten disease 5, 17, 47, 153
Anti-Phospholipids Breast, hematological malignancies, lung, colon-rectum, melanoma, kidney
RA, SLE, anti-phospholipid syndrome, 
systemic sclerosis, mixed connective 
tissue disease,  Behҫet’s disease, 
systemic sclerosis, systemic vasculitis
5, 11, 154-159
Anti-Dsg-1/Dsg-3 NHL, chronic lymphocytic leukemia PV 160, 161
Anti-Cytokeratin 8 Head and neck, breast, lung, cervix, bronchi, HCC RA, AIH 162-165
Anti-IMP HCC, breast, colon, prostate, ovary, 
stomach SLE
17, 34-36, 166,  
167
Anti-IFN-α Thymoma Autoimmune polyendocrinopathy syndrome type 1 5
Anti-α2-HSG Breast Autoimmune endometriosis 120, 168
HCC: Hepatocellular carcinoma; SLE: Systemic lupus erithematosus; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; RA: Rheumatoid arthritis; 
SS: Sjögren’s syndrome; SCLC: Small cell lung cancer; CENP: Centromere nuclear protein; NHL: non-Hodgkin lymphoma; Jo-1: Istidil-tRNA sintetasi; 
Sm: Smith antigen; snRNP: small nuclear ribonucleoprotein; AITD: Autoimmune thyroid disease; eIF-4G: Eukaryotic translation initiation factor-4G; CCP: 
Cyclic citrullinated peptide; RF: Rheumatoid factor; ASMA: Anti-smooth muscle antibodies; TPO: Thyroid peroxidase; DTC: Disseminated tumor cells; TG: 
Thyroglobulin; PV: Pemphigus vulgaris; HSP: Heat shock protein; GRP78: Glucose-regulated protein 78; ANNA: Anti-neuronal nuclear antibody; GAD: 
Glutamic acid decarboxylase; CA II: Carbonic anhydrase II; GADPH: Glyceraldehyde 3-phosphate dehydrogenase; SOD: Superoxide dismutase; ER: 
Estrogen receptor; AchR: Acetylcholine receptor; VGCC: Voltage-gated calcium channels; CD20: B-lymphocyte antigen CD20; CLL: Chronic lymphocytic 
leukemia; Dsg: Desmoglein; IMP: Insulin-like growth factor II mRNA-binding protein; IFN: Interferon; α2-HSG: α2-Heremans Schmid-glycoprotein.
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c) their concentration and type of microenvironment; d) 
their immunological/pro-inflammatory properties (170). 
Among the structural properties, the binding 
of a self antigen to nucleic acid or the presence 
of a highly charged surface, or repetitive surface 
elements, or a coiled-coil in a self antigen might 
promote autoreactive immune response (170). Other 
observations suggested that the removal of death 
cells could induce the production of antibodies to self 
antigens. Necrosis is commonly considered as a pro-
inflammatory and immunogenic type of death, which 
furnishes “danger signals” able to activate the innate 
immune response and then the adaptive immunity 
(171, 172). Indeed, self antigens are expressed on the 
surface of apoptotic or necrotic cells or, are modified 
by cell-death-mediated protein proteolysis or by 
molecules cleavage as occurs for nucleic acid antigens 
(170). The presence of cleavage sites for caspases, 
Granzyme B or cathepsins in autoantigens may lead to 
presentation of cryptic epitopes capable of stimulating 
autoreactive T and B lymphocytes (170, 173). 
Another important issue is related to 
changes in autoantigen cancer cells expression. The 
overexpression or the expression in aberrant place of 
a given self antigen could induce immune responses 
in cancer patients. In addition, autoantibodies 
generation may also be due to an altered protein 
structure. Neoepitopes exposure, mutations and 
post-translational antigens modifications, such 
as glycosylation, methylation, phosphorylation, 
sumoylation, citrullination, adenosine diphosphate-
ribosylation, ubiquitination, and acetylation, can 
overcome self tolerance mechanisms. In particular, 
post-translational modifications can influence the 
recognition of self antigen by the immune system, by 
affecting antigen processing, by binding and interaction 
of the MHC with the T cell receptor (TCR) (3). Targeting 
neoepitopes/neoantigens is a new therapeutic strategy 
for cancer, because these antigens might elicit specific 
T cell responses and lead to tumor regression (174, 
175).
The selection of the autoantibody repertoire 
shared by patients with cancer and autoimmune 
disease can be further influenced by the immunological 
and pro-inflammatory properties of a given self 
antigen. It has been demonstrated that several self 
antigens, including asparaginyl and histidyl-tRNA 
sinthetases, U3/fibrillarin, ssDNA plus La/SS-B, and 
topoisomerase I can act as chemoattractants for 
leukocytes when released from damaged cells, thus 
inducing inflammation and autoimmunity (5, 176).
Finally, an autoimmune response may be 
due to molecular mimicry. In fact an immune response 
against an infectious agent can elicit a cross-reaction 
against human proteins with structural similarity (173).
5. BIOLOGICAL ACTIVITIES OF AUTOANTI-
BODIES TO SELF ANTIGENS
Autoantibodies occurring both in cancer 
patients and in autoimmune diseases exert several 
biological and pathogenic effects, that can modulate 
tumor growth and survival. Table 2 reports examples 
of biological effects exerted by autoantibodies to self 
antigens (9, 64, 94, 132, 133, 154, 177-202).
Kowal et al. reported that autoantibodies 
against dsDNA found in cerebrospinal fluid have 
the ability to cross-react with the NR2 glutamate 
receptor, leading to apoptotic neuronal death in 
the mouse hippocampus (177). In addition, these 
autoantibodies generate an inflammatory response 
due to their deposition as immune complexes in 
kidney and are able to penetrate into living cells and 
triggering apoptosis in mesangial and endothelial 
cells (9). dsDNA autoantibodies possess both in 
vitro and in vivo anti-tumor activities through the 
induction of apoptosis in myeloma and fibrosarcoma 
cell lines (9). Antinuclear antibodies (ANAs) increase 
the inflammation through the formation of immune 
complexes that can induce the production of cytokines 
or can deposit in the kidney tissue leading to systemic 
lupus erythematosus. The extracellular release 
of nuclear antigens is essential for the formation 
of these immune complexes. It has suggested 
that the pyroptosis can trigger antigens release in 
genetically predisposed individuals (178). Robitaille 
et al. demonstrated that autoantibodies to CENP-B 
inhibited the CENP-B-mediated production of IL-8 and 
also the transactivation of EGFR in vascular smooth 
muscle cells (179). A recent study demonstrated the 
enhanced phagocytosis by neutrophils in RA patients 
owing RF and anti-CCP autoantibodies. They showed 
that these autoantibodies indirectly increased the 
phagocytic capacity of neutrophils. In addition, RF and 
anti-CCP antibodies possess the ability to activate the 
complement system cascades, leading to the increase 
of the inflammatory process and then tissue damage in 
RA (180). Anti-citrullinated protein antibodies (ACPAs) 
in patients with RA are associated with inflammation 
and subsequent joint destruction and deformity. ACPAs 
bind to monocyte surface-expressed citrullinated 
GRP78 and stimulate TNF-α production and decrease 
let-7a miRNA expression. Lu et al. demonstrated 
that ACPAs contribute to inflammation by stimulating 
TNF-β production via binding to citrullinated GRP78 
protein and following NF-κB activation on monocyte/
macrophages (181). Furthermore, Lu et al. recently 
observed the ACPAs bind to citrullinated HSP-60 on 
the plasmamembrane of the osteosarcoma cell line 
Saos-2 and induce apoptosis through Toll-like receptor 
4 (TLR4) signaling. Furthermore, ACPAs increase 
the expression of IL-6 and IL-8 in Saos-2 cells. RA 
patients with higher titer of anti-citrullinated HSP-60 
antibodies showed severe joint damage, suggesting 
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Table 2. Examples of biological activities of autoantibodies to self antigens found in cancer and in 
autoimmune disease patients.
Autoantibodies Biological activities References
Anti-dsDNA
Apoptotic neuronal death (mouse hippocampus) 177
Deposition of immune complexes in kidney and generation of inflammation, penetration in living cells, 
induction of apoptosis (mesangial and endothelial cells) 9
Induction of apoptosis (myeloma and fibrosarcoma cells) 9
Anti-Nuclear antigens Formation of immune complexes, increase of inflammation or deposition of immune complexes in the kidney 178
Anti-CENP-B Inhibition of CENP-B-mediated production of IL-8 and transactivation of EGFR in vascular smooth muscle cells 179
Anti-CCP Increase of phagocytic capacity of neutrophils and activation of complement system cascades 180
ACPA
Stimulation of TNF-α and -β production and decrease of let-7a miRNA expression; NF-κB activation 
on monocyte/macrophages via binding to citrullinated GRP78 181
Induction of apoptosis through TLR4 signaling via binding to citrullinated HSP-60 182
ANCA Activation of cytokine-primed neutrophils and production of ROS 183
Anti-TPO Activation of ADCC and CDC; anti-proliferative activity in papillary thyroid cancer cells 64, 184
Anti-GRP78 Induction of proliferation and protection of prostate cancer cells from TNF-induced apoptosis 94
Anti-GRP78 (COOH-
terminal domain)
Inhibition of cellular proliferation and induction of apoptosis in melanoma and prostate cancer cells 186, 187
Decrease invasion and increase H2O2-induced apoptosis of ovarian cancer cells 188
Anti-HSP60, -HSP70 Enhancement of pro-inflammatory cytokines and chemochines production via TLR signaling in monocyte cells 189
Anti-Hu Induction of neuronal cell death in the absence of T cell-mediated immune response or ADCC 190
Anti-Yo Induction of cytotoxicity through a non apoptotic cell death in Purkinjie cells 191
Anti-α-enolase
Induction of apoptosis in endothelial and retinal cells 193, 194
Reduction of the migration and invasion capacity of pancreatic ductal adenocarcinoma cells 195
Anti-Ribosomal P proteins
Inhibition of apolipoprotein B synthesis in hepatoma cells 196
Impairment of memory and induction of apoptosis in brain cells and in Jurkat cells; inhibition of cell 
proliferation by inhibition of activation of Erk and Akt 196
Delay of mammary carcinoma growth in a murine model of breast cancer 133
Inhibition of in vitro cancer cell growth in colon cancer cells 134
Anti-ER Erk activation and cell proliferation in breast cancer cells 142
Anti-AchR Activation of apoptolysis in pemphigus vulgaris 197
Anti-VGCC Block Ca2+ influx and inhibition of cell growth in SCLC cell lines 198
Anti-Phospholipids
Increase of leukocyte infiltration and tumor invasion in breast cancer 154
Alteration of the inner mitochondrial membrane and of the normal apoptotic turnover of the 
syncytiotrophoblast 199
Anti-Dsg1, -Dsg3 Induction of apoptosis through the increase of Bax, p53, Fas ligand and receptor, and activation of caspases; activation of EGFR- and apoptosis (FasR)-mediated signaling pathways 200
Anti-Aquaporin-4
Induction of oligodendrocyte death, myelin loss and neuron death through complement-dependent 
astrocyte cytotoxicity 201
Induction of astrocytopathy, in the absence of complement activation and immune cell infiltration in 
Devic’s neuromyelitis optica 202
dsDNA: Double-strand DNA; CENP-B: Centromere nuclear protein-B; IL: Interleukin; EGFR: Epidermal growth factor receptor; CCP: Cyclic citrullinated 
peptide; ACPA: Anti-citrullinated proteins antibody; TNF: Tumor necrosis factor; NF-κb: Nuclear factor- κB; GRP78: Glucose-regulated protein 78; TLR: 
Toll-like receptor; HSP: Heat shock protein; ANCA: Anti-neutrophil cytoplasmic antibody; ROS: Reactive oxygen species; TPO: Thyroid peroxidase; 
ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity; Erk: Extracellular signal-regulated kinases; Akt: Protein 
kinase B; ER: Estrogen receptor; AchR: Acetylcholine receptor; VGCC: Voltage-gated calcium channels; SCLC: Small cell lung cancer; Dsg: Desmoglein. 
a role of membrane-expressed citrullinated HSP-60 
and ACPAs in the pathogenesis of RA (182). Falk 
et al. demonstrated that anti-neutrophil cytoplasmic 
antibodies (ANCAs), through the binding to antigen 
on neutrophil surface, activate cytokine-primed 
neutrophils and produce reactive oxigen species 
(ROS). ANCAs also induces the release of primary 
granule contents. They suggested that ANCAs can 
release toxic oxygen radicals and noxious granule 
constituents leading to vascular injury in patients 
with pauci-immune necrotizing vasculitis and pauci-
immune crescentic glomerulonephritis (183). 
Autoantibodies to self antigens in cancer patients    
1296 © 1996-2017
Anti-TPO autoantibodies play a role in 
the induction of thyroid dysfunction and also in 
the progression of the disease through cytotoxic 
mechanisms. TPO autoantibodies can damage 
thyroid cells by antibody- and complement-
dependent cytotoxicity (ADCC and CDC). It has been 
demonstrated that monocytes are the effector cells 
and contribute with T cells to the destruction of thyroid 
gland mediated by anti-TPO antibodies in autoimmune 
thyroid disease (184). Anti-Tg autoantibodies are 
implicated in the destruction of thyroid gland and in the 
initiation of autoimmune thyroiditis (185). Furthermore, 
anti-TPO autoantibodies showed anti-proliferative 
activity in papillary thyroid cancer cells (64).
GRP78 is a chaperone protein of the 
endoplasmic reticulum and belong to the HSP70 family. 
It has been demonstrated that prostate cancer patients 
possess autoantibodies to GRP78, that bind to a site on 
the protein also recognized by its physiological agonist, 
α2-macroglobulin. These autoantibodies are able to 
induce proliferation of prostate cancer cells and protect 
them from TNF-induced apoptosis (94). In contrast, it 
has been reported that antibodies against the COOH-
terminal domain of GRP78 inhibit cellular proliferation 
and induce apoptosis in melanoma and prostate cancer 
cells (186, 187). Patients with ovarian cancer possess 
autoantibodies against the COOH-terminal domain 
of GRP78 and these antibodies show the ability to 
decrease invasion and increase H2O2-induced apoptosis 
of ovarian cancer cells, suggesting a protective role of 
these antibodies in this type of cancer (188). 
Several studies also demonstrated that 
autoantibodies against other HSPs exert biological 
activities. In particular anti-HSP60 autoantibodies 
are cytotoxic to endothelial cells, and anti-HSP60 
and -HSP70 autoantibodies also enhance pro-
inflammatory cytokines and chemochines production 
via TLR signaling in monocytic cells (189). 
Anti-Hu and anti-Ri antibodies were shown 
to be internalized and accumulated into hippocampal 
and cerebellar neurons, but only anti-Hu antibodies 
were able to induce neurone cell death, in the absence 
of T cell-mediated immune response or antibody-
dependent cellular cytotoxicity (190). It has also 
reported that anti-Yo antibodies have the capacity 
to induce citotoxicity through a non apoptotic cell 
death, but only in Purkinjie cells (191). Indeed, anti-Yo 
antibodies recognize cytoplasmic 62 kDa Yo antigen 
in Purkinje cell. This antigen plays an essential role 
in Purkinje cell survival and thus the binding of the 
antibody can induce cell death (192). 
Anti-α-enolase autoantibodies were able to 
induce apoptosis in endothelial and in retinal cells (193, 
194). In particular, these antibodies were able to inhibit 
the catalytic function of enolase, to deplete ATP, to 
elevate intracellular Ca2+, leading to Bax translocation 
to the mitochondria and release of cytochrome c into 
the cytoplasm (194). In addition, it has been reported 
that the in vitro and in vivo inhibition of α-enolase-1 
with specific monoclonal antibodies reduces the 
migration and invasion capacity of pancreatic ductal 
adenocarcinoma cells. This activity could be a 
characteristic of patients with pancreatic cancer who 
possess autoantibodies against α-enolase (195). 
Several studies analyzed the biological 
activities of anti-ribosomal P protein antibodies. Anti-
ribosomal P protein antibodies inhibit apolipoprotein 
B synthesis by inducing cellular dysfunction in 
hepatoma cell lines. In Jurkat cells the antibodies are 
able to penetrate in cells and induce apoptosis (196). 
Other studies reported that anti-ribosomal P protein 
antibodies interact with several neuronal surface P 
antigen in hippocampal neurons, leading to impaired 
memory and brain cell apoptosis. Indeed, these 
antibodies penetrate in neuronal cells and inhibit cell 
proliferation through the inhibition of the activation of 
Erk and Akt proteins (196). We have demonstrated 
that the cellular stress induce an increased expression 
of the C-22 P0 epitope on cell membrane of pharynx 
cancer cell lines (132). In addition, it was reported that 
ectopic overexpression of P0 increases cell proliferation 
in breast and liver carcinoma cell lines. In our study, 
we demonstrated that BALB-neuT mice vaccinated 
with the human P0 protein showed a significant delay 
of mammary carcinoma growth and that the inhibition 
of tumor growth was associated with high serum 
levels of antibodies against P0 (133). In addition, we 
demonstrated the presence of a spontaneous humoral 
immune response to ribosomal P0 protein in colorectal 
cancer patients and the inhibition of in vitro cancer cell 
growth after C-22 P0 epitope targeting (134). 
A recent study showed that antibodies against 
estrogen receptor (ER) found in patients with breast 
cancer, contribute to the pathogenesis of this cancer, 
because are able to act as estrogen agonists, leading to 
Erk activation and cell proliferation (143). Chernyavski 
et al. reported that patients with Phemphigus vulgaris 
(PV) produce antibodies that bind to AChR present on 
the cell membrane and on mitochondria. 
The mitochondrial AChR can regulate the 
cytochrome c release by inhibiting mitochondrial 
permeability, leading to inhibition of the intrinsic pathway 
of apoptosis. In PV, this activity of mitochondrial AChR 
is abolished by the antibodies, leading to activation of 
apoptolysis (197). Autoantibodies to presynaptic P/Q-
type VGCC in Lambert-Eaton myasthenic syndrome 
are able to block Ca2+ influx through voltage-gated 
calcium channels in SCLC cell lines, thus suggesting 
that in vivo they may interfere with tumor growth (198). 
Several studies showed that anti-
phospholipids autoantibodies exert different biological 
activities. Wu et al. reported that the presence of 
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anti-phospholipids autoantibodies is associated 
with invasive tumors in breast cancer patients. 
These autoantibodies are capable of increasing 
leukocyte infiltration and tumor invasion, leading to 
acceleration of tumor angiogenesis and progression. 
Anti-phospholipids autoantibodies can induce the 
expression of Tissue Factor (TF) and VEGF in 
endothelial cells and monocytes (154). In addition, it has 
been reported that anti-phospholipids autoantibodies 
are internalized into the syncytiotrophoblast and 
affect the inner mitochondrial membrane and alter the 
normal apoptotic turnover of the syncytiotrophoblast. 
Indeed, anti-phospholipids autoantibodies are able to 
increase proton leak through the inner mitochondrial 
membrane and to decrease the ability of the ATPase 
to produce ATP, leading to necrosis (199). Anti-Dsg1 
and anti-Dsg3 are the main autoantibodies found in 
patients with PV. These autoantibodies are able to 
induce apoptosis through the increase of Bax, p53, 
Fas ligand and receptor (FasR) and activation of 
caspases. In addition, PV autoantibodies are able to 
bind to EGFR and to activate EGFR- and apoptosis 
(FasR)-mediated signaling pathways (200). Several 
studies have been demonstrated that antibodies to 
aquaporin-4 have the ability to diffuse in all central 
nervous system structures, including the optic nerve 
and spinal cord, and to induce oligodendrocyte 
death, myelin loss and neuron death. These effects 
are mediated by complement-dependent astrocyte 
cytotoxicity, through leukocyte infiltration, cytokines 
release and blood-brain barrier disruption (201). A 
recent report also demonstrated that aquaporin-4 
antibodies can induce astrocytopathy, in the absence 
of complement activation and immune cell infiltration in 
Devic’s neuromyelitis optica (202). 
6. ASSOCIATION OF AUTOANTIBODIES TO 
SELF ANTIGENS WITH PARANEOPLASTIC 
AUTOIMMUNE SYNDROMES
The presence of autoantibodies to self 
antigens can be associated with paraneoplastic 
autoimmune syndromes and revealed by the occurrence 
of neurological syndromes as well as metabolic, 
rheumatic, cutaneous and haematological disorders 
in cancer patients due to the biological activities 
of the elicited immunoglubulins (40, 98, 203-228). 
Autoantibodies to onconeural antigens can induce in 
cancer patients cerebellar degeneration (anti-Hu, anti-
neuronal Na(+)/K(+) ATPase, anti-ZIC4, anti-Yo, anti-
CV2, anti-Tr, anti-mGluR1, Anti-Ma2, anti-Ri and anti-
VGCC autoantibodies), encephalomyeloneuropathy 
(anti-PCA2, anti-Hu, anti-CV2, anti-Amphiphysin and 
anti-VGCC autoantibodies), sensory neuropathy (anti-
Hu, anti-CV2 and anti-amphiphysin autoantibodies), 
retinopathy (anti-CV2, anti-TRMP1 and anti-Recoverin 
autoantibodies), DADS neuropathy (anti-MAG and 
anti-CENP-F autoantibodies), myasthenia gravis (anti-
AchR autoantibodies), Lambert-Eaton myasthenic 
syndrome (anti-SOX1 and anti-VGCC autoantibodies), 
neuromyelitis optica (anti-Aquaporin-4 autoantibodies), 
Stiff-person syndrome (anti-Amphiphysin 
autoantibodies) and limbic encephalitis (anti-Hu, anti-
Ma2, anti-NMDAR and anti-AMPAR autoantibodies) 
(98, 203-219). Anti-GAD autoantibodies induce 
paraneoplastic diabetes mellitus in SCLC or PGA2 
in hepatocellular carcinoma patients (220, 221). 
Paraneoplastic pemphigus is characterized by the 
occurrence of autoantibodies to plakin family proteins 
in patients with haematological neoplasms, carcinomas 
and melanoma (222). The occurrence of anti-nuclear 
antibodies induces the lupus-like syndrome, the 
polyarteritis nodosa and the Raynaud’s phenomenon 
in cancer patients (223). Anti-CCP autoantibodies were 
reported to induce polyarthritis in lung cancer patients 
(224). The paraneoplastic autoimmune multiorgan 
syndrome can arise in cancer patients for the presence 
of anti-plakins, anti-plectin and a2-macroglobulin-
like-1 molecule autoantibodies (225, 226). Finally, 
anti-red cells and -platelets autoantibodies can induce 
autoimmune hemolytic anemia and thrombocytopenia 
in cancer patients, respectively (40, 227, 228). An 
example of the occurrence of autoantibodies in cancer 
patients associated with paraneoplastic autoimmune 
syndromes are reported in Table 3. 
7. ROLE OF AUTOANTIBODIES TO SELF 
ANTIGENS AS BIOMARKERS FOR CANCER 
DETECTION AND CANCER PATIENTS  
PROGNOSIS
The presence of autoantibodies to self-
antigens has been investigated as a marker for cancer 
detection and for predicting survival of cancer patients. 
Examples of these autoantibodies are reported in 
Table 4. Several techniques were used to discover 
novel tumor antigens able to elict autoantibodies, 
including serological analysis of tumor antigens by 
recombinant cDNA expression cloning (SEREX), 
serological proteome analysis (SERPA), multiple 
affinity protein profiling (MAPPing) and high-density 
protein microarrays (229). However, the confirmation 
of the association of antibodies to tumor antigens 
with clinical parameters, and thus their potential 
use as biomarkers for early detection of cancer 
and cancer patients prognosis, needs validation by 
employing recombinant protein ELISA (Enzyme-
Linked Immunosorbent Assay), protein microarrays 
and bead-based immunoassay (166, 229). However, 
the usefulness of autoantibodies as markers for 
cancer patients prognosis is still controversial (229). 
In addition, immune response to tumor antigens 
could also be enhanced or decreased after standard 
therapies. For example, we have demonstrated that 
radiotherapy increased the levels of autoantibodies 
to P0 protein and decreased those to collagens, 
fibronectin and HSP90 in prostate cancer patients 
(74). In addition, a recent study reported that the levels 
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Table 3. Pattern of autoantibodies to self antigens detected in cancer patients and associated with paraneoplastic 
syndromes.
Autoantibodies Cancer site or histological
subtype
Paraneoplastic Autoimmune Syndromes References
Neurological Syndromes





Encephalomyelitis, sensory neuropathy, cerebellar ataxia, 
limbic encephalitis 98, 203
Anti-neuronal Na+/K+ ATPase Colon Brainstem and cerebellar syndrome 204
Anti-ZIC4 Ovary, SCLC Paraneoplastic cerebellar syndrome 205, 206
Anti-Yo (PCA-1) Ovary, breast, uterus Paraneoplastic cerebellar degeneration 98, 207
Anti-CV2/CRMP-5 SCLC, thymoma  
Encephalomyeloneuropathy with corea, 
encephalomyelitis, sensory-motor neuropathy, uveitis, 
retinopathy, cerebellar ataxia
98, 208
Anti-Aquaporin-4 Lung, ovarian teratoma Neuromyelitis optica, longitudinally extensive transverse myelitis 216, 217
Anti-Amphiphysin SCLC, breast Stiff-person syndrome, sensory-motor neuropathy, encephalomyelitis 98
Anti-SOX1 SCLC Lambert-Eaton myasthenic syndrome 215
Anti-MAG Colon-rectum DADS neuropathy 214
Anti-CENP-F Colon-rectum DADS neuropathy 214
Anti-Ri (ANNA-2) SCLC, breast Opsoclonus-myoclonus, cerebellar ataxia 98
Anti-Ma2 (Ta) Testis, lung Limbic-diencephalic encephalitis, subacute cerebellar degeneration, myeloradiculopathy 98, 210
Anti-TRMP1 Melanoma Retinopathy 212, 213
Anti-Recoverin SCLC Retinopathy 98
Anti-Tr (PCA-Tr) Hodgkin’ disease Cerebellar ataxia 98
Anti-mGluR1 Prostate Cerebellar degeneration 209
Anti-AchR Thymoma Miasthenia gravis 98
Anti-NMDAR Ovarian teratoma Limbic Encephalitis 218
Anti-VGCC SCLC, breast, lymphoma 
Encephalopathy, ataxia, myelopathy, neuropathy, 
neuromuscular junction disorder, myopathy, Lambert-
Eaton myasthenic syndrome, subacute cerebellar 
degeneration
98, 211
Anti-AMPAR Breast Limbic encephalitis 219
Metabolic Sindromes
Anti-GAD SCLC, HCC Diabetes mellitus, PGA2 220, 221
Skin and Mucous Membrane Syndromes
Anti-Plakin family proteins 
(desmoplakins I and II, BP230, 
periplakin, Envoplakin, Dsg-3 and/or 
Dsg-1)
Haematological neoplasms, 
carcinomas and melanoma Pemphigus 222
Anti-Plakins, Anti-Plectin, a2-
macroglobulin-like-1 molecule
NHL, CLL, Castleman 
disease, pancreas, colon, 
breast, prostate, liver, 
tongue, bronchi, cervix, 
kidney 
Paraneoplastic autoimmune multiorgan syndrome 225, 226
Rheumatic Syndromes
Anti-CCP Lung Polyarthritis 224
ACA, ANA




ANA Ovary, breast, head and neck, meningioma Lupus-like syndrome 223
ANCA Kidney, colon ANCA-associated vasculitis 223
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ANA Stomach, lung angiomatoid fibrous histiocytoma Polyarteritis nodosa 223
Hematological  Syndromes
Anti-red cells B cell lymphoma, colon, leukemia, kidney AIHA 227, 228
Anti-phospholipids, platelet 
glycoproteins Lymphoproliferative disease AITP 228
PCA: Purkinje cell cytoplasmic antibody; SCLC: Small cell lung cancer; ANNA: Anti-neuronal nuclear antibody; ZIC4: Zinc finger protein of cerebellum; 
CV2/CRMP-5: Collapsin response-mediator protein-5; MAG: Myelin-associated glycoprotein; DADS: Distal acquired demyelinating symmetric; CENP-F: 
Centromere nuclear protein-F; TRMP1: transient receptor potential cation channel, subfamily M, member 1; mGluR1: Metabotropic glutamate receptor 
type 1; AchR: Acetylcholine receptor; NMDAR: N-methyl-D-aspartate receptor; VGCC: Voltage-gated calcium channels; AMPAR: Alpha-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor; GAD: Glutamic acid decarboxylase; HCC: Hepatocellular carcinoma; PGA2: Polyglandular autoimmune 
syndrome type 2; Dsg: Desmoglein; NHL: Non Hodgkin lymphoma; CCP: Cyclic citrullinated peptide; ACA: Anti-centromere antibody; ANA: Anti-nuclear 
antibodies; ANCA: Anti-neutrophil cytoplasmic antibodies; AIHA: Autoimmune hemolytic anemia, AITP: Autoimmune thrombocytopenia.
Table 4. Examples of autoantibodies to self antigens proposed as biomarkers or associated with cancer 
patients prognosis.
Type of tumor Autoantibodies Signature of cancer as compared to control groups or prevalence
Survival or Prognosis 
or Recurrences References
Breast cancer
Anti-P0 Significant (Prevalence of 10.6%) No correlation with clinical stage 133
Anti-Annexin XI-A, -Ku, 
-Ribosomal protein S6 Significant NA 231
Anti-MUC-1 glycoforms Significant Lower incidence of metastases 232
Anti-CENP-B Signifcant (Prevalence of 33%) Longer DFS and OS 233
Anti-p53 Significant Shorter 5-year survival 234
Anti-p53 Prevalence of 9% Shorter survival 235
Anti-SOX2 Significant (Prevalence of 18.4%) NA 236
Anti-FKBP52, -PPIA, -PRDX2 Significant NA 237
Anti-PARP1, -BRCA2 Significant (Prevalence of 15.3% and 36.6% respectively) NA 238
Anti-HER2, -p53, -CEA, 
-Cyclin-B1 Significant NA 239
Anti-EPHA2, -IGFBP2, -CST2, -GAL1, 
-HER-2, -LAMC2, -ANGPTL4, -DKK1, 
-MUC1, -SSR2, -SPINT2, -SPON2
Significant NA 240
Anti-c-Myc, -Survivin, -Cyclin-B1, 
-Cyclin-D1, -p62, -p53, -p16, -CDK2
Significant (Sensitivity of 61%, 
specificity of 89%) NA 241
Anti-Imp1, -p16, -Koc, 
-Survivin, -Cyclin-B1, -c-Myc
Significant (Sensitivity of 67.3%, 
specificity of 92.2% ) NA 242
Anti-p90/CIP2A Significant NA 242
Anti-IMP2/p62 Significant (Prevalence of 14.3%) NA 242
Anti-MDM2, -c-Myc Significant Shorter DFS (anti-c-Myc) 33
Anti-HuC or -HuD Significant (Prevalence of 23.3%) NA 96
Anti-p53 Significant (Prevalence of 20.6%) Poor prognosis 244
Anti-p53 Significant No association with survival or disease stage 245, 246, 247
Anti-ANXA1 Significant (Sensitivity of 23%, specificity of 90%) NA 248
Anti-CCNY Significant (Sensitivity of 23.5%, specificity of 95.5% ) Poor prognosis 249
Anti-IGFBP-2 Significant (Sensitivity of 73.2%, specificity of 90%) NA 250
Anti-p16 Significant (Sensitivity of 19.7%, specificity of 60.6%)
Association with 
advanced stage 251
Anti-Chromogranin A Significant (Sensitivity of 47.6%, specificity of 80.0%) NA 252
Autoantibodies to self antigens in cancer patients    
1300 © 1996-2017
Lung cancer
Anti-SMOX, -NOLC1, -MALAT1, 
-HMMR
Significant (Sensitivity of 47.5%, 
specificity of 97.3%) NA 253
Anti-NY-ESO-1, -XAGE-1, -ADAM29, 
-MAGEC1
Significant (Sensitivity of 33%, 
specificity values of 96%)
Association with 
advanced stage 254
Anti-p53, -NY-ESO-1, -CAGE, -SOX2, 
-GBU4-5,-Annexin 1
Significant (Sensitivity of 34%, 
specificity of 91%)
No differences between 
disease stage 255
Anti-14-3-3ζ, -c-Myc, -MDM2, , -p16, 
-p53, -Nucleophosmin, -Cyclin-B1
Significant (Sensitivity of 68.9%, 
specificity of 79.5%) NA 256
Anti-KIAA037, -ROCK1, -PRKCB1, 
-TACC2, -C14ORF145, -ARFGAP3, 
-YBX1, - SOX2 homologous
Significant (Prevalence of 15%) NA 257
Anti-monophosphate dehydrogenase, 
-fumarate hydratase, -α-enolase, 
endoplasmic reticulum protein 29, 
-Annexin 1, -hydrosteroid 17-β 
dehydrogenase, -MTAP
Significant NA 258
Anti-TTC14, -BRAF, -CTAG1B, 
-ACTL6B, -MORC2 Significant NA 259
Anti-p62, -BIRC, -Livin-1, -p53, -PRDX, 
-NY-ESO-1, -Ubiquitin Significant NA 260
Anti-p53 NA Lower probability of OS and DFS 262
Anti-p53 NA No association with survival 265
Esophagus cancer
Anti-CD25 Significant NA 266
Anti-FOXP3 Significant (Sensitivity of 22.7%, specificity of 95%) NA 267
Anti-p16 Significant (Prevalence of 5.7%) NA 268
Anti-c-Myc, -HCCR, -p53, -p62 Significant NA 269
Gastric cancer
Anti-p53 Significant Longer survival 270
Anti-p53 Prevalence of  20.3% Poor prognosis 271
Anti-p53 Prevalence of  31% NA 272
Anti-p53 Prevalence of  12.2% Shorter survival 273
Anti-GRP78 Prevalence of  28.3% NA 274
Anti-MAGEA4, -CTAG1, 
-p53, -ErbB2_C, -SDCCAG8 Significant NA 275
Anti-p53, -Koc, -p62, -c-Myc, 
-IMP1, -Survivin, -p16 Prevalence of 64% NA 276
Anti-CT antigens (-MAGEC1, 
-MAGEA3, -CTAG2, -CTAG1B) Significant NA 277
Colorectal cancer
Anti-dsDNA Significant Less incidence of recurrences 10
Anti-p53 Significant No association with survival 31
Anti-P proteins Significant (Prevalence of 10.4%) NA 134
Anti-p53 Prevalence of 25% Shorter survival 278
Anti-PIM1, -MAPKAPK3, -ACVR2B Significant (Sensitivity of 84.1%, specificity of 71.4%) NA 279
Hepatocellular 
carcinoma
Anti-Nucleophosmin 1 Significant (Prevalence 24.4%) NA 26
Anti-c-Myc, -p53, -Cyclin-B1, 
-p62, -Koc, -IMP, -Survivin Significant (Prevalence of 59.9%) NA 42
Anti-p53 Significant Shorter survival 280
Anti-p53 Significant NA 281
Anti-Sui1, -RalA Significant (Prevalence of 11.7% and 19.5%, respectively) NA 282
Anti-DDX3, -eEF2, -AIF, -hnRNP A2, 
-PBP, -TIM Significant NA 283
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Anti-AFP, -Gankyrin, -GPC-3, -IMP1, 
-p62, -Koc, -p53, -c-Myc, -Cyclin-B1, 
-HuD, -Survivin, -MAGEA4, -p16, 
-SOX-2, -CAGE, -NY-ESO-1, -GBU4-5
21 TAAs (Specificity 92%, sensitivity 
45%; high risk positivity 21%) NA 284
Anti-p53 NA Shorter survival 285
Anti-p53 Prevalence of 7% Higher survival rate without recurrence 286
Anti-AFP Significant NA 287, 288
Pancreatic cancer Anti-DDX48 Significant (Prevalence of 33.33%) NA 289
Ovarian cancer
Anti-IMP, -IMP2/p62 Significant (Prevalence of 26.5% and 29.4% respectively) NA 43
Anti-PARP1, - BRCA1 Significant (Prevalence of 29.4% and 50.0% respectively) NA 238
Anti-p53 Prevalence of 15% No association with OS 290
Anti-p53 Prevalence of 25% (serum) and of 19% (ascites)
Unfavorable DFS and OS 
(Ascites autoantibodies) 291
Anti-p53 Significant Improved OS 292
Anti-p53 Prevalence of 12.4% No association with survival 293
Anti-p53 Prevalence of 19% Shorter OS and DFS 294
Anti-CFL1, -EZR, -JUP, -HIST1H1C, 
-HNRNPAB, -HSPA9, -PDZD11, -PFN1, 
-PP1A, -SERF2, -TUBA1C
Significant NA 295
Anti-p53, -PTGFR,-PTPRA, -ACSBG1, 




No association with OS 
(pooled uni-multivariate 
HRs). Association with a 
better OS with a pooled 








Anti -60S ribosomal protein L7, 
-MARCKS1 homologous
Significant (discrimination between 
prostate cancer patients and patients 
with prostatic benign hyperplasia)
NA 299
Anti-MUT, -RAB11B, -CSRP2, -SPOP, 
-ZNF671
Discrimination between prostate 
cancer patients with low from those 
with high inflammation (Sensitivity of 






Anti-ALK Prevalence of 38% Lower incidence of relapse 301
NA: Not Available; MUC: mucin; CENP-B: centromere nuclear protein-B; DFS: disease-free survival; OS: overall survival; FKBP: FK506 binding protein; 
PPIA: Peptidylprolyl isomerase A; PRDX: peroxiredoxin; PARP1: Poly(ADP-ribose) polymerase 1; BRCA2: Breast related cancer antigen 2; HER2: 
Receptor tyrosine-protein kinase erbB-2; CEA: carcinoembryonic antigen; EPHA2: Ephrin type-A receptor 2; IGFBP2: Insulin-like growth factor-binding 
protein 2; CST2: Cystatin-SA; GAL1: Galactokinase 1; LAMC2: Laminin subunit gamma 2; ANGPTL4: Angiopoietin-like 4; DKK1: Dickkopf-related protein 
1; SSR2: serine-rich repeat protein 2; SPINT2: Kunitz type serine peptidase inhibitor 2; SPON2: spondin 2; p90/CIP2A: cancerous inhibitor of PP2A; 
IMP2/p62: IGF2 mRNA-binding protein 2; CCNY: Cyclin Y; SMOX: spermine oxidase; NOLC1: Nucleolar and coiled-body phosphoprotein 1; MALAT1: 
Metastasis-associated lung adenocarcinoma transcript 1; HMMR: Hyaluronan mediated motility receptor; XAGE-1: X antigen family member-1; ADAM29: 
ADAM metallopeptidase domain 29; MAGEC1: MAGE family member C1; CAGE: Cancer-associated gene; ROCK1: Rho-associated, coiled-coil-containing 
protein kinase 1; PRKCB1: Protein kinase C beta 1; TACC2: Transforming acidic coiled-coil-containing protein 2; C14ORF145: Human centrosomal protein 
of 128 kDa; ARFGAP3: ADP-ribosylation factor GTPase activating protein 3; YBX1: Y box binding protein 1; MTAP: Methylthioadenosine phosphorylase; 
TTC14: tetratricopeptide repeat domain 14; BRAF: B-Raf proto-oncogene, serine/threonine kinase; ACTL6B: Actin like 6B; MORC2: MORC family CW-
type zinc finger 2; CTAG1: cancer/testis antigen 1; BIRC: Baculoviral inhibitors of apoptosis repeat containing; CD25: Alpha chain of the IL-2 receptor; 
FOXP3: Forkhead box P3; GRP78: Glucose-regulated protein 78; SDCCAG8: Serologically defined colon cancer antigen 8; dsDNA: Double-strand DNA; 
MAPKAPK3: MAP kinase-activated protein kinase 3; ACVR2B: Activin receptor type-2B; RalA: Ras-related protein Ral-A; DDX: DEAD-box protein; eEF2: 
Eukaryotic elongation factor 2; AIF: Apoptosis-inducing factor; hnRNP: Heterogeneous nuclear ribonucleoprotein; PBP: Prostatic binding protein; TIM: 
T-cell immunoglobulin and mucin-domain; AFP: Alpha-fetoprotein; GPC-3: Glypican-3; CFL1: Cofilin 1; EZR: Ezrin; HIST1H1C: Histone cluster 1 H1 
family member C; HSPA9: Heat shock protein family A (Hsp70) member 9; PDZD11: PDZ domain-containing protein 11; PFN1: Profilin-1;  PP1A: Protein 
phosphatase 1A; SERF2: Small EDRK-rich factor 2; TUBA1C: Tubulin alpha 1C; JUP: Junction plakoglobin; PTGFR: Prostaglandin F receptor; PTPRA: 
Protein tyrosine phosphatase, receptor type A; ACSBG1: Acyl-CoA synthetase bubblegum family member 1; CSNK1A1L: Casein kinase 1 alpha 1 like; 
DHFR: Dihydrofolate reductase; PRL: Prolactin; PSMC1: Proteasome 26S subunit, ATPase 1; HR: Hazard ratio; MUT: Methylmalonyl-CoA mutase; 
CSRP2: Cysteine and glycine-rich protein 2; SPOP: Speckle-type POZ protein; ZNF671: Zinc finger protein 671; ALK: Anaplastic lymphoma kinase. 
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of autoantibodies against galectin-3 could be useful to 
predict the efficacy of chemotherapy in patients with 
lung adenocarcinoma (230). 
Autoantibodies to a single antigen including 
p53, CENP-B, annexin XI-A, the p80 subunit of the Ku 
antigen, ribosomal protein S6, ribosomal P0 protein, 
p90/CIP2A, SOX2, IMP2/p62 and glycoforms of MUC1 
could significantly discriminate breast cancer patients 
from healthy donors (26, 133, 231-236). To improve 
cancer detection, recent studies have analyzed the 
presence of autoantibodies to a panel of antigens. 
For example autoantibodies to FKBP52, PPIA, and 
PRDX2, to PARP1 and BRCA1/BRCA2 or to HER2, 
p53, CEA, and cyclin-B1 were significantly detected in 
cancer patients as compared to healthy controls (237-
239). Overall a combination of autoantibodies against 
different antigens allowed to discriminate cancer 
patients from healthy donors and autoantibodies to 
HER2 and p53 could be detected in prediagnostic 
cancer patient sera (239-242). Anti-p53 autoantibodies 
were associated with a shorter patients survival (234, 
235). Conversely, the presence of anti-CENP-B 
autoantibodies was associated with prolonged DFS 
and OS, and that to MUC1 glycoforms to a lower 
incidence of metastases and increased time to 
metastasis (232, 233).
Several studies have demonstrated the 
presence of significant levels of autoantibodies in 
lung cancer patients as compared to healthy donors 
(33, 96, 243-265). Circulating autoantibodies to 
individual p53, annexin A1-derived peptide antigens, 
CCNY, IGFBP-2, p16, chromogranin A-derived 
peptides were significantly higher in cancer patients 
than control subjects (243-252). Autontibodies to 
two or more antigens including HuC/HuD, SMOX/
NOLC1/MALAT1 and HMMR, NY-ESO-1/XAGE-1/
ADAM29, and MAGEC1, p53/NY-ESO-1/CAGE, 
GBU4-5/Annexin 1 and SOX2, 14-3-3ζ/-c-Myc/
MDM2/Nucleophosmin 1/p16/p53 and cyclin-B1, 
p62/BIRC/Livin-1/p53/Peroxiredoxin/NY-ESO-1 and 
Ubiquitin, and several other antigens combination 
were analyzed for improving the sensitivity and 
specificity of the assays for discriminating cancer 
patients from healthy donors (33, 96, 253-260). In 
addition, autoantibodies to p16, NY-ESO-1, XAGE-
1, ADAM29, and MAGEC1 were associated with 
advanced disease stages, those to c-Myc were 
related to shortened DFS and those to p53 or to CCNY 
were linked to shorter survival or worse prognosis 
(33, 243, 244, 249, 251, 254, 261, 262). Conversely, 
ANAs were linked to a better patients survival (263). 
Other reports detecting autoantibodies to p53 could 
not reveal any association with patients survival or 
disease stage (245-247, 255, 264, 265).
Serum of patients with digestive tract tumors 
was analyzed for the presence of autoantibodies 
to self antigens too (266-277). The prevalence of 
autoantibodies to CD25, or FOXP3, or p16 was 
significantly higher in esophageal squamous cell 
carcinoma patients than in the control groups (266-
268). In addition, autoantibodies to a panel of four 
antigens (c-Myc, HCCR, p53 and p62) showed high 
diagnostic accuracy for esophageal cancer (269). 
Autoantibodies to p53 or GRP78 were detected 
with higher prevalence in gastric carcinoma patients 
than in healthy donors (270-274). The survival time 
of gastric carcinoma patients testing positive for 
anti-p53 autoantibodies was significantly longer than 
that of testing negative patients (270). However, 
p53 autoantibodies were predictor of an unfavorable 
prognosis in other studies (271, 273). Combination of 
autoantibodies against five tumor-associated antigens 
(TAAs) (MAGEA4 + CTAG1 + TP53 + ERBB2_C + 
SDCCAG8) was able to increase the percentage of 
positive gastric cancer patients (275). In the study 
performed by Zhou et al., the sensitivity and the 
specificity for autoantibodies against seven TAAs 
(Anti-p53, -Koc, -p62, -c-Myc, -IMP1, -Survivin and 
-p16) in diagnosing gastric cardia adenocarcinoma 
reached up to 64% and 87%, respectively (276). By 
applying a T7 phage display-based serological analysis 
of recombinant cDNA expression libraries technique 
it was identified a representative set of antigens 
eliciting humoral responses in gastric cancer patients. 
45-autoantibodies signature could discriminate gastric 
cancer patients from healthy donors (277). 
The prevalence of autoantibodies to dsDNA 
or p53 or P proteins were higher in patients with 
colorectal cancer than in healthy subjects (10, 31, 134, 
278). The prevalence of simultaneous autoantibodies 
to PIM1, MAPKAPK3, and ACVR2B were able to 
discriminate between colorectal cancer and control 
samples with a sensitivity of 84.1% and a specificity 
of 71.4% (279). No correlation was found between 
colorectal cancer patients survival and anti-p53 
autoantibodies (31). Conversely, in another study a 
shorter survival characterized patients positive for 
anti-p53 autoantibodies (278). In addition, patients with 
anti-dsDNA autoantibodies showed a less incidence of 
recurrences after a 3-year follow-up (10).
The prevalence of autoantibodies against 
p53, or, nucleophosmin was higher in HCC 
patients than that in healthy donors (26, 280, 281). 
Autoantibodies to multiple tumor-associated antigens 
were shown to enhance detection of HCC showing 
higher prevalence in HCC patients than in chronic 
hepatitis and normal donor sera (42, 282-284). A 
shorter patients survival time was observed in HCC 
patients displying anti-p53 autoantibodies (280, 285). 
On the other hand, a study reported that HCC patients 
having anti-p53 autoantibodies had higher survival rate 
without recurrence (286). In addition, autoantibodies 
to α-fetoprotein were more prevalent in HCC patients 
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than in healthy donors or liver cirrhosis and chronic 
hepatitis patients (287, 288).
Reactivity to DDX48 was observed in 20 of 
60 (33.33%) pancreatic cancer patients while none of 
the 60 normal individuals analyzed had anti-DDX48 
autoantibodies (289). 
The high prevalence of autoantibodies to p53, 
IMP1 and IMP2/p62, PARP1 and BRCA1, or to a panel 
of different antigens suggested that autoantibodies 
could be potential biomarkers in immunodiagnosis 
of ovarian cancer (43, 238, 290-296). However, 
there is not an agreement for the prognostic value of 
anti-p53 autoantibodies. Shortened OS and RFS or 
unfavorable DSF and OS were reported in ovarian 
cancer patients harboring serum or ascites anti-p53 
autoantibodies, respectively (291, 294). Conversely, 
one study reported that anti-p53-autoantibodies were 
prognostic for improved OS (292). Other studies 
reported no association with patients survival (290, 
293). Finally, the presence of anti-p53 autoantibodies 
was significantly associated to a better OS when only 
multivariate HRs were pooled together (4 studies) 
(297). 
Autoantibodies to multiple antigens 
were detected in prostate cancer patients (298-
300). Massoner et al. found autoantibodies to 408 
different antigens and reported that 174 of these 
were solely detected in cancer patients compared 
to healthy donors (298). Autoantibodies to antigens 
fragments with homology to 60S ribosomal protein 
L7, and MARCKS1 were able to discriminate prostate 
cancer patients from patients with benign prostatic 
hyperplasia (299). The presence of autoantibodies 
to MUT, RAB11B, CSRP2, SPOP and ZNF671 was 
able to distinguish prostate cancer patients with low 
from those with high inflammation with a sensitivity of 
80% and a diagnostic specificity of 67% (300). None 
of these studies investigated the prognostic values of 
autoantibodies. 
Finally, high antibody titers to ALK (prevalence 
38%) correlated with significantly lower cumulative 
incidence of relapses in pediatric anaplastic lymphoma 
kinase-positive anaplastic large cell lymphoma (301). 
8. PARANEOPLASTIC NEUROLOGICAL  
SYNDROMES, EFFECTS OF THERAPY TAR-
GETING IMMUNE-CHECKPOINT RECEPTORS 
AND Tregs DYSREGULATION IN AUTOIMMUNE 
DISEASE PATIENTS: THE CROSSROAD 
BETWEEN AUTOIMMUNITY AND IMMUNE 
RESPONSE IN CANCER PATIENTS
From studies regarding patients with 
paraneoplastic neurological syndromes we have 
learned that antibodies to self antigens might reflect 
the attempt to counteract tumor growth and might 
affect cancer patients survival (302, 303). Patients 
survival analysis showed a significantly shorter 
median survival time from the diagnosis of SCLC in 
SCLC patients without Lambert-Eaton myasthenic 
syndrome than in those with Lambert-Eaton 
myasthenic syndrome (304). Dalmau et al. analyzed 
71 patients with “paraneoplastic” encephalomyelitis 
or sensory neuronopathy, or both who had serum 
anti-Hu antibodies. Most of the patients (78%) had 
small-cell lung cancer. In 9 patients no tumor was 
revealed. Thus, the authors searched for the presence 
of the tumor that when detected was frequently small 
and localized or was detected only at autopsy (305). 
Peterson et al. reviewed the clinical findings in 55 
patients with cerebellar degeneration associated 
with the anti-Yo autoantibodies. Fifty-two of them had 
cancers, mainly limited to the involved organs (breast 
and gynecological tract) and local lymph nodes. 
One woman had lung adenocarcinoma, and in three 
no malignancy was identified. In 34 of 52 patients 
with cancer, the neurologic syndrome preceded the 
cancer diagnosis and in many led to the diagnosis 
(306). Graus et al. found that the presence of anti-
Hu autoantibodies in patients with paraneoplastic 
encephalomyelitis/sensory neuropathy and SCLC 
is a strong and independent predictor of complete 
response to the therapy and that this feature accounts 
for the association between anti-Hu autoantibodies 
and longer cancer patients survival (307). Honnorat et 
al. found that the median survival time was significantly 
longer in patients with SCLC and anti-CV2/CRMP5 
autoantibodies as compared to patients with SCLC 
and anti-Hu autoantibodies, thus suggesting that the 
prognosis of the same type of tumor may be dependent 
on the type of onconeural autoantibodies (308). Hetzel 
et al. suggested that the immune response evoked 
against cancer cells and probably cross-reactive with 
cerebellar cells, might affect the metastatic process. 
Indeed, the authors found that in 8 patients who had 
primary stage III gynecological cancer and anti-Purkinje 
cell autoantibodies as compared to 24 control patients 
without paraneoplastic cerebellar degeneration there 
was no difference in the volume of the primary tumor 
but a significantly smaller volume of the metastatic 
tumor in the autoantibodies-positive group (309). In a 
prospective analysis of the presence of self-antigens 
autoantibodies and of mortality in 238 SCLC patients, 
Gozzard et al., observed an independent survival 
advantage associated with anti-neuronal nuclear 
antibodies (ANNAs) (310). On the other hand, Rojas 
et al. by retrospectively analyzing the clinical outcome 
and prognostic factors in a series of 34 patients with 
paraneoplastic cerebellar degeneration and anti-
Yo autoantibodies found that the overall prognosis 
of cancer patients was rather poor, particularly for 
patients with gynecologic tumors (311). In addition, in 
some reports tumor was shown to regress in patients 
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with paraneoplastic neurological degeneration (303). 
Zaheer et al. described a case of small SCLC that 
spontaneously regressed in concomitant with the 
occurrence of a paraneoplastic neurological syndrome 
and the presence of anti-neuronal antibodies (312). 
Darnell described a spontaneous regression of a lung 
mass in a patient with both the anti-Hu and atypical anti-
neuronal antibodies and subacute sensory neuropathy 
(302). In addition they found that one patient survived 
8 years free of disease and was positive for the anti-
Hu autoantibodies and another patient survived 6 
years after spontaneous tumor regression and had 
anti-neuronal autoantibodies (302). Mawhinney et al. 
reported that a paraneoplastic sensory neuropathy 
with high titers of anti-Hu autoantibodies, was 
associated with lung tumor regression (313). Similarly, 
Gill et al. reported a case of a patient with anti-Hu 
autoantibodies associated paraneoplastic sensory 
neuronopathy who had a spontaneous regression of 
the small cell lung cancer (314). Hirano et al. observed 
a partial spontaneous regression of a SCLC tumor 
associated with a progression of paraneoplastic 
sensory neuropathy and the presence of anti-neuronal 
autoantibodies in a 55-year-old woman (315). 
Villers et al. reported a paraneoplastic amyopathic 
dermatomyositis associated with the regression of a 
primary melanoma (316). 
The microenvironment within the tumor can 
support the growth of cancer cells trough the release 
of growth factors and immunosuppressive cytokines 
by endothelial cells, immune cells and mesenchymal 
stromal cells (MSC) (317). Among the others, Tregs 
are key regulators of the immune responses, avoiding 
abnormal immune system activation and autoimmunity 
(318). Tregs have shown to suppress the activity of 
effector T cells, Natural Killer (NK) cells and dendritic 
cells either by cell-cell contact or by the secretion of 
immunosuppressive cytokines (IL-10 and TGFβ) and 
indoleamine-2,3-dioxygenase (IDO) (318). On the other 
hand, MDSCs stimulate chronic tissue inflammation 
and suppression of immune response by the release 
of reactive oxygen species, nitric oxide, arginase-1 
and cytokines and by the recruitment and induction 
of Tregs and immunosuppressive tumor-associated 
macrophages (TAM) in the tumor microenvironment 
(318). Several inhibitory pathways are involved in 
maintaining immune self-tolerance thus preventing 
autoimmune diseases and exaggerate immune 
responses to pathogens (319). The occurrence of an 
autoimmune disease is a sign of a merged deficiency 
of both central and peripheral immune tolerance 
inducing the activation of autoreactive T cells (5). 
Tregs express immune-checkpoint receptors, 
including cytotoxic T-lymphocyte-associated antigen 4 
(CTLA4), programmed cell death protein 1 (PD1), T cell 
membrane protein 3 (TIM3), adenosine A2a receptor 
(A2aR), lymphocyte activation gene 3 (LAG3) that are 
essential for the development of self-tolerance (319). In 
addition, the negative regulatory checkpoint receptors 
can be dysregulated by cancer cells to suppress anti-
tumor activity of immune response (319). CTLA4 
regulates the magnitude of T cells activation during the 
initial stage of the immune response. Indeed, CTLA4 
expression on the membrane of T cells reduces their 
activation by competing with CD28 in the binding with 
B7.1 and B7.2 in addition to provide inhibitory signals 
to T cells, thus activating the immune suppressive 
functions of Tregs (319). On the other hand, PD1 
reduces the activation of T cells in peripheral tissue 
by directly interfering with T cell receptor signaling 
and restricts autoimmune phenomena (320). Cancer 
cells expressing PD1 ligands (PDL1 and PDL2) 
lead to T cells exhaustion or anergy (319, 320). In 
addition, PD1 is expressed by B and NK cells (321). 
The upregulation of PD1 ligands on cancer cells may 
be constitutive due to tumor cells abnormal signaling 
pathways activation and may lead to innate immune 
resistance or may mirror cancer cells adaptation to the 
anti-tumor response thus leading to adaptive immune 
resistance (319). Accordingly, CTLA4 (ipilimumab), 
PD1 (nivolumab and pembrolizumab) and PD-L1 
antibodies were employed in clinical trials in patients 
with a variety of tumor types showing a clinical 
response (321, 322). Of note, two phase III clinical 
trials employing the ipilimumab have shown improved 
survival of patients with advanced melanoma (321). 
Nivolumab treatment of metastatic melanoma patients 
induced an objective response rate of 40% and overall 
survival rate of 72.9% as compared to an objective 
response rate of 13.9% and overall survival rate of 
42.1% obtained with dacarbazine chemotherapy (321). 
Since the mechanisms of CTLA4 and PD1 are distinct, 
combined treatment with both antibodies CTLA4 and 
PD1 were employed (321). A Phase I clinical trial 
conducted in patients with advanced melanoma, 
showed that concurrent therapy with nivolumab and 
ipilimumab induced rapid and deep tumor regression 
in a substantial proportion of patients which appears 
to be distinct from that observed employing single 
therapy (323). Recently an anti-PDL1 monoclonal 
antibody, avelumab, was proven to block PD1/PDL1 
interaction, to mediate ADCC of cancer cells (324). 
In addition, a phase I study reported its non toxicity 
(324).
Other clinical trials are ongoing to evaluate 
the efficacy of combination therapies by using anti-
CTLA4 or anti-PD1 antibodies and epacadostat, an 
IDO1 enzyme inhibitor. Indeed, IDO1 is an intracellular 
immunoregolatory enzyme involved in tumor escape, 
tolerance and immunosuppression. IDO-expression 
has been identified as a prognostic marker of 
survival in several cancers and IDO upregulation 
is a critical mechanism of resistance to anti-cancer 
immunotherapy with CTLA4 antibodies. It has been 
recently demonstrated that epacadostat was able 
to increase dendritic cells antigen presentation, to 
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decrease Tregs proliferation and to increase CTLs 
activity. Thus the combined therapies by using an 
inhibitor of IDO1 represent a promising strategy in 
cancer immunotherapy (325). 
On the other hand, the blockade of 
immune-checkpoint receptors by antibodies 
induces inflammatory adverse effects that mimic an 
autoimmune response (320). A patient with advanced 
mucosal melanoma who received four doses of a fully 
human monoclonal antibody against PD1 (MK-3475) 
had a durable near-complete response but developed 
severe hypothyroidism, rhabdomyolysis, and acute 
kidney injury (326). Therapy with a combination of 
ipilimumab and nivolumab, was associated with a 
22% incidence of either thyroiditis or hypothyroidism 
and a 9% incidence of hypophysitis in melanoma 
patients (327). Michot et al. reviewed the immune-
related adverse events (IRAE) found in cancer 
patient after immune-checkpoint receptors blockade 
(328). The authors reported that skin immune-related 
event especially vitiligo is the most frequent IRAE 
after blockade of the immune-checkpoint receptors 
in patients with melanoma. Other dermatological 
reactions encompassed rash/erythema and toxic 
epidermal necrosis (328). A small percentage (5%) of 
patients declared dry mouth and showed the presence 
of ANAs. Diarrhoea was developed in about 30% of 
the patients after anti-CTLA4 therapy while colitis after 
the same treatment resembled the characteristic of 
Crohn’s disease. In addition, by reviewing the literature 
they found that some patients (5-10%) receiving 
antibodies to immune-checkpoint receptor developed 
endocrine diseases such as thyroid dysfunctiosn and 
hypophysitis for a deficient release of ACTH, TSH, 
FSH, LH, growth hormone or prolactin (328). IRAE 
might be also characterized by autoimmune hepatitis, 
immune-related- and organizing inflammatory-
pneumonitis. Ophthalmological IRAEs (episcleritis, 
conjunctivitis, uveitis, etc) and neurological 
syndromes (posterior reversible encephalopathy, 
transverse myelitis, Guillan Barré syndrome, etc) 
have been described in patients receiving anti-
CTLA4 antibodies (328). The presence of ANAs and 
anti-CCP autoantibodies characterized IRAE such 
as polyarthritis in patients after anti-CTLA4 therapy. 
Renal and pancreatic disorders were also seen in 
a small percentage of CTLA4 and PD1 antibodies-
treated patients. Finally, hematological disorders 
including autoimmune neutropenia or pancytopenia, 
red cells aplasia have been described after patients 
anti-CTLA4 therapy (328). The authors concluded that 
the dysimmune toxicity might be associated with the 
antitumor response in cancer patients (328). 
The value of Tregs dysfunction in generating 
an immune response has been consolidated in 
patients with paraneoplastic syndromes while the 
increase of Tregs has been associated with poor 
prognosis in cancer patients (329). Zhang et al. 
reported that patients with paraneoplastic neurological 
syndrome, anti-Hu autoantibodies and SCLC showed 
lymphopenia of CD3+ and CD4+ T cells, increased 
proportions of total activated T cells and activated 
CD4+ T cells, and reduced numbers of Tregs (329). 
Tani et al. found that the expression levels of FOXP3, 
TGF-β and CTLA4 mRNA in Treg-rich subsets of 
paraneoplastic neurological syndrome patients were 
down-regulated compared with that of SCLC patients 
without paraneoplastic neurological syndrome 
(330). Wang et al. showed that Treg infiltration was 
an indicator of a poorer prognosis for breast cancer 
patients (331). Higher Tregs frequencies were 
observed in early phase of bladder cancer growth and 
in larger tumors with more aggressive type of invasion 
(332). A strong immunosuppressive microenvironment 
in metastatic lymph nodes from patients with cervical 
cancer with high Tregs levels, low CD8+ T cell/Tregs 
ratio, and high levels of PD-L1+ and HLA-DR+- 
myeloid cells was reported by Heeren et al. (333). 
Therefore, immune suppression through Tregs or other 
types of suppressive cells resident within the tumor 
microenvironment, appears to be a major mechanism 
of tumor immune escape (334). 
The association between autoimmunity, 
immune response to self antigens in cancer patients 
and anti-tumor effects obtained targeting Tregs in 
cancer patients is disclosed by the dysfunction of Tregs 
observed in patients developing autoimmune diseases 
(335). Tregs dysfunctions including loss of Foxp3 
expression (exTreg), self-skewed TCR repertoire 
and atypical Treg functions including the expression 
of vascular endothelial growth factor or expression of 
RANKL have been shown to turn in pathogenic Tregs in 
several disease models (335). The alteration of Tregs 
is a key pathogenic occurrence which induces a multi-
organ autoimmunity that characterizes the immune 
dysregulation, polyendocrinopathy, enteropathy and 
X-linked (IPEX) syndrome (336). Tregs alterations 
may lead to melanocyte loss in vitiligo, rheumatoid 
arthritis, type 1 diabetes and autoimmune thyroiditis 
(337-340) (Figure 1). 
In view of all these findings, the biological 
activity of antibodies observed in cancer patients 
showing paraneoplastic syndrome might resemble 
the activation of immune response in cancer patients 
in the absence of immunosuppression. Indeed, the 
IRAE observed after immune-checkpoint receptors 
antibodies therapy might reflect a humoral and cell-
mediated antitumor response.
9. CONCLUSIONS
Several studies have shown that cancer 
patients develop autoantibodies to self antigens with 
higher prevalence than healthy donor or patients 
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with inflammatory disease. The repertoire of cancer 
patients autoantibodies in part overlaps that of 
autoimmune disease patients. Overall, the occurrence 
of autoantibodies is not followed by a better survival 
of cancer patients. However, the tumor-targeting 
autoantibodies induced in cancer patients deal with the 
immunosuppressive milieu in which they are developed 
and in which they would trigger their biological effects. 
On the other hand, autoimmune disorders often 
develop after alterations of tolerance checkpoints 
which induce Tregs dysfunctions and drive towards 
pro-inflammatory responses. Due to these different 
immunological microenvironments, autoantibodies 
with similar specificities may have different effects in 
cancer and autoimmune disease patients. Biological 
activities of autoantibodies to self antigens may induce 
paraneoplastic syndrome in cancer patients which 
might reflect the attempt of the patients to counteract the 
tumor growth. Recent studies have shown that patients 
with paraneoplastic syndrome have a spontaneous 
regression of tumors. The value of Tregs dysfunction 
in generating an immune response has been 
consolidated in patients with paraneoplastic syndromes 
while the increase of Tregs has been associated with 
poor prognosis in cancer patients. Accordingly, novel 
therapies have employed antibodies which target 
Tregs immune-checkpoint receptors. Encouraging 
results have been obtained following such therapy in 
cancer patients. The blockade of immune-checkpoint 
receptors by antibodies in cancer induces inflammatory 
adverse effects that mimic an autoimmune response in 
absence of immunosuppression.
Overall, the biological activities of 
autoantibodies in cancer might depend on their 
specificity, on their immunological properties and 
on the presence of a favorable microenvironment. 
Autoantibodies found in cancer patients can be used 
as tool for the diagnosis of cancer. 
The current knowledge on the spontaneous 
humoral responses occurring in cancer patients, on the 
mechanisms that trigger self antigens autoantibodies 
and on the mechanisms of their biological activities 
might help to furnish a rationale to design anti-cancer 
immunotherapeutic protocols.
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